HealthcareLarge capRs 64,557 crRs 61.3 cr traded a dayManufacturingHealthcarePharmaceuticals
Close on 2026-08-21
5,400.00
0.00%
52-week range34% of the way up
5,144.505,890.00
Market cap
64,557 cr
P/E (TTM)
29.3×
industry 44×
EPS (TTM)
184.38
Revenue YoY
+10.9%
Q1 FY27
Profit YoY
-22.0%
Net margin
13.9%
-5.9pt vs a year ago
Growth trend
-3.7pt
vs last quarter’s YoY
1 month
-3.6%
Below 52w high
9.1%
RSI (14)
30
Daily swing
2.4%
average true range
Volume
0.6×
vs 20-day average
Traded
Rs 61 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
1 week
+0.60%
1 month
−3.61%
3 months
+0.37%
6 months
−6.12%
1 year
+2.93%
The read
written from the numbers on this page
The evidence leans constructive6 supporting, 3 against, 0 worth knowing
Supporting
up 3% over twelve months
matches near a 52-week low, which has beaten the market by +0.45 points over 20 sessions across 47,393 past signals
3 independent kinds of evidence agree today, which is uncommon
revenue grew 11% year on year in the quarter ending 2026-06-30
priced at 29× earnings against an industry median of 44× — 33% below its peers
futures show a long buildup — the move is being funded by new positions
Against
trading 2% below its 200-day average
1 of the scans it matches has historically underperformed the market
net margin has narrowed from 19.5% to 13.9% across four quarters
Worth knowing
nothing the data supports either way
ALKEM sits in Manufacturing, Healthcare, Pharmaceuticals — worth checking whether the whole group is moving together or whether this name is doing it alone.
What would change this read: a close back above 5,534, its 200-day average; open interest reversing while price keeps going.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
read from the filings, with the figure behind every line
Working1
Revenue +10.9% year on year, Rs 3,371 cr to Rs 3,740 cr.
+10.9%Rs 3,371 crRs 3,740 cr
Needs watching3
Net margin moved from 19.8% to 13.9%.
19.8%13.9%
Profit grew slower than revenue, -22.0% against +10.9%.
-22.0%+10.9%
Net profit -22.0% year on year, Rs 668 cr to Rs 521 cr.
-22.0%Rs 668 crRs 521 cr
Every figure here is computed from the company’s own filings. The wording is generated directly from the figures.
How it has performed
price return over each window, measured against zero
What the scans say today
4 of 47 matched on 2026-08-21
ALKEM matches 4 of the 47 scans today, across 3 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
ALKEM trades at 29× trailing earnings, close to its median of 28× over this window. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Analyst call filings were typically +0.14pt vs the market over the next 5 sessions (n=3,352) · AGM / EGM filings were typically +0.00pt vs the market over the next 5 sessions (n=4,362) · Other filing filings were typically -0.08pt vs the market over the next 5 sessions (n=12,093)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 11% against the same quarter a year earlier
net margin widened from 7.0% to 13.9%
Going against it
profit dropped 22% year on year
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
2026-06-30 · consolidated
3,740
772
521
43.49
13.9%
Q4 FY26
2026-03-31 · consolidated
3,603
423
251
19.77
7.0%
Q3 FY26
2025-12-31 · consolidated
3,737
781
653
53.19
17.5%
Q2 FY26
2025-09-30 · consolidated
4,001
896
779
63.99
19.5%
Q1 FY26
2025-06-30 · consolidated
3,371
771
668
55.56
19.8%
Q4 FY25
2025-03-31 · consolidated
3,144
396
322
25.57
10.3%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average-2.6%
Versus 200-day average-2.4%
Below 52-week high-8.3%
Above 52-week low+5.0%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)30.3
Higher closes in last 53 of 5
Six-month return−6.12%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)2.43%
Volume versus 20-day0.6x
Median daily turnoverRs 61.3 cr
Derivatives
near expiry 2026-08-25 · 2026-08-20
Long Buildup
Price up, open interest up. New buyers are arriving rather than old sellers leaving — the move is being funded, not squeezed.
Futures basis versus spot-0.13%
Open interest change+0.2%
Put / call ratio0.41
Put wall (support)5,000
Call wall (resistance)5,700
Max pain5,450
How to read this
Open interest is contracts still open, so a rise means new positions and a fall means positions closing. Combined with price direction that gives the state on the left. The walls are the strikes carrying the most open interest near expiry — levels other people are watching, not levels the price is obliged to respect. A future below spot means sellers are paying to be short.
Peers
Healthcare · 67 classified companies
ALKEM trades at 29.3× trailing earnings against an industry median of 44.0× across 64 other classified companies in its industry — cheaper than them, by 33%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.
largest twelve by market capitalisation. Market cap and P/E need filed financials, so blanks are companies whose filings have not been read yet
Recent sessions
what this stock has matched since the engine went live
This is the live record, not the backtest — the scans this stock actually appeared in on each stored session. A name that keeps reappearing is in a persistent condition; a one-day appearance usually is not.
Session
Scans
Which
2026-08-21
1
Opened and closed at the same price
2026-08-20
3
Range is tightening, Opened and closed at the same price, Tightest range in 4 days
2026-08-19
3
Trading far more than usual, Lost the 200-day line, Falling on heavy volume